drugset
drugset / Trial / NCT04567667

Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male Participants

NCT04567667 ↗

Phase 1 Completed 9 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess the way the body absorbs, distributes, breaks down and eliminates radioactive BMS-986278 as well as the safety and tolerability of BMS-986278 in healthy male participants.

Timeline

Start
2020-10-15
Primary completion
2021-04-11
Completion
2021-04-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Admilparant Small molecule — —
Background sincalide Peptide — —

Indications

No indication recorded.